Abstract:Proteolysis-targeting chimeras (PROTACs) are essential bifunctional molecules that target proteins of interest (POIs) for degradation by cellular ubiquitination machinery. Despite significant progress made in understanding PROTACs' functions, their therapeutic potential remains largely untapped. As a result of the success of highly flexible, scalable, and low-cost mRNA therapies, as well as the advantages of the first generation of peptide PROTACs (p-PROTACs), we present for the first time an engineering mRNA PROTACs (m-PROTACs) strategy. This design combines von Hippel-Lindau (VHL) recruiting peptide encoding mRNA and POI-binding peptide encoding mRNA to form m-PROTAC and promote cellular POI degradation. We then performed proof-of-concept experiments using two m-PROTACs targeting two cancer-related proteins, estrogen receptor alpha and B-cell lymphoma-extra large protein. Our results demonstrated that m-PROTACs could successfully degrade the POIs in different cell lines and more effectively inhibit cell proliferation than the traditional p-PROTACs. Moreover, the in vivo experiment demonstrated that m-PROTAC led to significant tumor regression in the 4T1 mouse xenograft model. This finding highlights the enormous potential of m-PROTAC as a promising approach for targeted protein degradation therapy. We developed mRNA proteolysis-targeting chimeras (PROTACs), a novel type of PROTACs, which incorporate mRNAs encoding E3 ligase recruiting peptide ligand and protein of interest (POI)-binding peptide ligand to promote cellular POI degradation. For the first time, we demonstrated that the encoding peptide PROTACs could degrade POIs and inhibit cell proliferation more effectively than the traditional peptide PROTACs, indicating their tremendous potential for targeted protein degradation therapy. image

Peptide-based PROTAC degrader of FOXM1 suppresses cancer and decreases GLUT1 and PD-L1 expression

Targeting of the FOXM1 Oncoprotein by E3 Ligase-Assisted Degradation

Mrna PROTACs: Engineering PROTACs for High‐efficiency Targeted Protein Degradation

Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy

Stimuli-activatable PROTACs for precise protein degradation and cancer therapy

PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy

In Vitro and in Vivo Degradation of Programmed Cell Death Ligand 1 (PD-L1) by a Proteolysis Targeting Chimera (PROTAC).

mRNA PROTACs: engineering PROTACs for high-efficiency targeted protein degradation

An engineered DNA aptamer-based PROTAC for precise therapy of p53-R175H hotspot mutant-driven cancer

Development of an Interfering Peptide M1-20 with Potent Anti-Cancer Effects by Targeting FOXM1.

A cell-permeable peptide-based PROTAC against the oncoprotein CREPT proficiently inhibits pancreatic cancer

A region-confined PROTAC nanoplatform for spatiotemporally tunable protein degradation and enhanced cancer therapy

Proteolysis Targeting Chimera (Protac) For Epidermal Growth Factor Receptor Enhances Anti-Tumor Immunity In Non-Small Cell Lung Cancer

Promising Proteolysis-Targeting Chimera for Mutant p53-R175H

Proteolysis-targeting chimeras (PROTACs) in cancer therapy

Enzyme-catalyzed Activation of Pro-PROTAC for Cell-selective Protein Degradation

New-generation advanced PROTACs as potential therapeutic agents in cancer therapy

ClickRNA-PROTAC for Tumor-Selective Protein Degradation and Targeted Cancer Therapy

Discovery of a proteolysis targeting chimera (PROTAC) as a potent regulator of FOXP3

Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future

[Advances in targeted delivery of proteolysis targeting chimeras in cancer therapy]